Literature DB >> 16026905

Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine.

Y Z Ghendon1, S G Markushin, I I Akopova, I B Koptiaeva, E A Nechaeva, L A Mazurkova, I F Radaeva, T D Kolokoltseva.   

Abstract

Optimal conditions are determined for growing cold-adapted reassortant strains of a live influenza vaccine in MDCK cell line cultivated in a fermenter with a serum-free medium and microcarriers. The studied MDCK cell line meet all national and WHO requirements for the finite cell lines used for the production of biological preparations. CA reassortant vaccine strains grown in such conditions which fully preserve its mutations and the mutations lead to amino acid substitution in all genome segments of the studied CA reassortants. Under optimal cultivation conditions, the output of a monovalent live CA influenza vaccine in a 10-l fermenter may reach 100,000 doses.

Mesh:

Substances:

Year:  2005        PMID: 16026905     DOI: 10.1016/j.vaccine.2005.04.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses.

Authors:  Ming-Wei Chen; Ting-Jen Rachel Cheng; Yaoxing Huang; Jia-Tsrong Jan; Shiou-Hwa Ma; Alice L Yu; Chi-Huey Wong; David D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-02       Impact factor: 11.205

Review 2.  Cell-based influenza vaccines: progress to date.

Authors:  Jennifer M Audsley; Gregory A Tannock
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice.

Authors:  Jae Won Rhee; Dongbum Kim; Byung Kwon Park; Sanghoon Kwon; Sunhee Cho; Ilseob Lee; Man-Seong Park; Jae-Nam Seo; Yong-Sun Kim; Hong Seok Choi; Younghee Lee; Hyung-Joo Kwon
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

4.  The new temperature-sensitive mutation PA-F35S for developing recombinant avian live attenuated H5N1 influenza vaccine.

Authors:  Wenting Zhang; Jiagang Tu; Zongzheng Zhao; Huanchun Chen; Meilin Jin
Journal:  Virol J       Date:  2012-05-23       Impact factor: 4.099

5.  Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.

Authors:  Allen Chen; Swan Li Poh; Christian Dietzsch; Elisabeth Roethl; Mylene L Yan; Say Kong Ng
Journal:  BMC Biotechnol       Date:  2011-08-11       Impact factor: 2.563

Review 6.  Current and emerging cell culture manufacturing technologies for influenza vaccines.

Authors:  Ernest Milián; Amine A Kamen
Journal:  Biomed Res Int       Date:  2015-03-01       Impact factor: 3.411

Review 7.  Alternative Experimental Models for Studying Influenza Proteins, Host-Virus Interactions and Anti-Influenza Drugs.

Authors:  Sonja C J H Chua; Hui Qing Tan; David Engelberg; Lina H K Lim
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-30

8.  Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.

Authors:  Verena Lohr; Yvonne Genzel; Ingo Jordan; Dietmar Katinger; Stefan Mahr; Volker Sandig; Udo Reichl
Journal:  BMC Biotechnol       Date:  2012-10-30       Impact factor: 2.563

Review 9.  Scientific barriers to developing vaccines against avian influenza viruses.

Authors:  Kanta Subbarao; Tomy Joseph
Journal:  Nat Rev Immunol       Date:  2007-04       Impact factor: 53.106

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.